Payment overview · 2025
General Payments
$172.74
11 reported records · 7 companies
Healthcare provider profile · identity verified
Ilya Schwartzman, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, IN · NPI 1144252552
Verified facts
What the public records show
CMS Open Payments records show Ilya Schwartzman, MD received $172.74 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.30 | 27.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.40 | 25.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.41 | 13.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.79 | 9.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.30 | 8.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $13.98 | 8.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.56 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $172.74 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.30 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.62 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.62 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 396 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 362 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 291 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 60 |
| Losartan Potassium | Losartan Potassium | 225 | 60 |
| Omeprazole | Omeprazole | 204 | 54 |
| Metformin Hcl Er | Metformin Hcl | 168 | 50 |
| Glimepiride | Glimepiride | 158 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 38 |
| Furosemide | Furosemide | 150 | 46 |
| Gabapentin | Gabapentin | 141 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 40 |
| Doxazosin Mesylate | Doxazosin Mesylate | 136 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 43 |
| Potassium Chloride | Potassium Chloride | 115 | 34 |
| Allopurinol | Allopurinol | 103 | 26 |
| Simvastatin | Simvastatin | 103 | 28 |
| Alendronate Sodium | Alendronate Sodium | 96 | 29 |
| Eliquis | Apixaban | 95 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 23 |
| Mounjaro | Tirzepatide | 76 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 19 |
| Prednisone | Prednisone | 74 | 47 |
| Sertraline Hcl | Sertraline Hcl | 73 | 18 |
| Tramadol Hcl | Tramadol Hcl | 72 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 27 |
| Montelukast Sodium | Montelukast Sodium | 66 | 18 |
| Trazodone Hcl | Trazodone Hcl | 62 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 15 |
| Donepezil Hcl | Donepezil Hcl | 54 | 15 |
| Lovastatin | Lovastatin | 54 | 13 |
| Synthroid | Levothyroxine Sodium | 52 | 15 |
| Spironolactone | Spironolactone | 51 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 15 |
| Atenolol | Atenolol | 45 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Fenofibrate | Fenofibrate | 41 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Metformin Hcl | Metformin Hcl | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 15 |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Topiramate | Topiramate | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Klor-Con 8 | Potassium Chloride | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $172.74 · 11 records | ABBVIE INC. | FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ohtuvayre, Ozempic, TRELEGY ELLIPTA, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error